Table 3.
Estimated SARS-CoV-2 outcomes averted through vaccination programme by number of doses received, Jan 3 to April 10, 2021
| Population size | SARS-CoV-2 infections averted | COVID-19-related hospitalisations averted | Severe or critical COVID-19-related hospitalisations averted | COVID-19-related deaths averted | |
|---|---|---|---|---|---|
| Individuals who were at least partly vaccinated* | |||||
| Age 16–24 years | 1 258 389 | 17 443 (14 839 to 20 047) | 347 (−6 to 699) | 57 (−34 to 149) | 5 (−5 to 15) |
| Age 25–34 years | 1 231 583 | 20 762 (17 393 to 24 131) | 904 (222 to 1586) | 229 (−35 to 493) | 10 (−11 to 32) |
| Age 35–44 years | 1 156 876 | 24 255 (19 821 to 28 690) | 1273 (339 to 2207) | 579 (8 to 1150) | 26 (−28 to 81) |
| Age 45–54 years | 981 651 | 28 634 (22 440 to 34 828) | 2544 (785 to 4303) | 1595 (283 to 2907) | 130 (−117 to 377) |
| Age 55–64 years | 782 447 | 24 421 (18 141 to 30 701) | 3316 (1169 to 5463) | 2361 (601 to 4120) | 326 (−198 to 850) |
| Age 65–74 years | 675 369 | 20 332 (13 242 to 27 422) | 4908 (1551 to 8265) | 3575 (835 to 6315) | 1045 (−282 to 2373) |
| Age 75–84 years | 319 285 | 15 025 (7456 to 22 594) | 6868 (1828 to 11 908) | 5461 (1085 to 9838) | 2070 (−262 to 4402) |
| Age ≥85 years | 133 311 | 7793 (2567 to 13 018) | 4437 (733 to 8141) | 3575 (322 to 6828) | 1920 (−242 to 4083) |
| Age ≥16 years | 6 538 911 | 158 665 (144 640 to 172 690) | 24 597 (18 942 to 30 252) | 17 432 (12 770 to 22 094) | 5532 (3085 to 7982) |
| Age ≥65 years | 1 127 965 | 43 150 (31 582 to 54 717) | 16 213 (9053 to 23 372) | 12 611 (6423 to 18 800) | 5035 (1393 to 8678) |
| Individuals who were fully vaccinated† | |||||
| Age 16–24 years | 1 258 389 | 10 282 (8755 to 11 810) | 220 (−8 to 448) | 33 (−19 to 86) | 4 (−3 to 11) |
| Age 25–34 years | 1 231 583 | 12 919 (10 842 to 14 997) | 580 (128 to 1032) | 140 (−24 to 305) | 6 (−4 to 16) |
| Age 35–44 years | 1 156 876 | 17 063 (13 983 to 20 144) | 877 (211 to 1543) | 398 (−0·4 to 797) | 18 (−16 to 52) |
| Age 45–54 years | 981 651 | 21 698 (17 112 to 26 283) | 1931 (568 to 3293) | 1199 (193 to 2205) | 101 (−79 to 281) |
| Age 55–64 years | 782 447 | 19 219 (14 384 to 24 053) | 2598 (899 to 4297) | 1844 (455 to 3234) | 253 (−143 to 649) |
| Age 65–74 years | 675 369 | 16 337 (10 694 to 21 981) | 3954 (1221 to 6687) | 2865 (653 to 5078) | 831 (−213 to 1874) |
| Age 75–84 years | 319 285 | 12 390 (6121 to 18 659) | 5762 (1504 to 10 020) | 4599 (906 to 8291) | 1669 (−227 to 3565) |
| Age ≥85 years | 133 311 | 6092 (1886 to 10 297) | 3545 (544 to 6546) | 2847 (223 to 5472) | 1469 (−217 to 3154) |
| Age ≥16 years | 6 538 911 | 116 000 (106 072 to 125 928) | 19 467 (15 200 to 23 735) | 13 925 (10 408 to 17 445) | 4351 (2559 to 6140) |
| Age ≥65 years | 1 127 965 | 34 819 (25 428 to 44 211) | 13 261 (7300 to 19 222) | 10 311 (5169 to 15 454) | 3969 (1022 to 6914) |
| Individuals who were partly vaccinated‡ | |||||
| Age 16–24 years | 1 258 389 | 7161 (6084 to 8237) | 127 (2 to 251) | 24 (−15 to 63) | 1 (−2 to 4) |
| Age 25–34 years | 1 231 583 | 7843 (6551 to 9134) | 324 (94 to 554) | 89 (−11 to 188) | 4 (−7 to 16) |
| Age 35–44 years | 1 156 876 | 7192 (5838 to 8546) | 396 (128 to 664) | 181 (8 to 353) | 8 (−12 to 29) |
| Age 45–54 years | 981 651 | 6936 (5328 to 8545) | 613 (217 to 1010) | 396 (90 to 702) | 29 (−38 to 96) |
| Age 55–64 years | 782 447 | 5202 (3757 to 6648) | 718 (270 to 1166) | 517 (146 to 886) | 73 (−55 to 201) |
| Age 65–74 years | 675 369 | 3995 (2548 to 5441) | 954 (330 to 1578) | 710 (182 to 1237) | 214 (−69 to 499) |
| Age 75–84 years | 319 285 | 2635 (1335 to 3935) | 1106 (324 to 1888) | 862 (179 to 1547) | 401 (−35 to 837) |
| Age ≥85 years | 133 311 | 1701 (681 to 2721) | 892 (189 to 1595) | 728 (99 to 1356) | 451 (−25 to 929) |
| Age ≥16 years | 6 538 911 | 42 665 (38 568 to 46 762) | 5130 (3742 to 6517) | 3507 (2362 to 4649) | 1181 (526 to 1842) |
| Age ≥65 years | 1 127 965 | 8331 (6154 to 10 506) | 2952 (1753 to 4150) | 2300 (1254 to 3346) | 1066 (371 to 1764) |
Data are n or number of cases averted with 95% CI in parentheses.
*
Individuals who were at least partly vaccinated were those who received at least one dose of BNT162b2 with at least 14 days of follow-up after the first dose.
†
Fully vaccinated individuals are people who received two doses of BNT162b2 with at least 7 days of follow-up after the second dose.
‡
Partly vaccinated individuals are people who received only one dose of BNT162b2 with at least 14 days of follow-up after the first dose or two doses with less than 7 days of follow-up after the second dose.